Fairhurst Robin A, Knoepfel Thomas, Leblanc Catherine, Buschmann Nicole, Gaul Christoph, Blank Jutta, Galuba Inga, Trappe Jörg, Zou Chao, Voshol Johannes, Genick Christine, Brunet-Lefeuvre Peggy, Bitsch Francis, Graus-Porta Diana, Furet Pascal
Novartis Institutes for BioMedical Research , CH-4002 Basel , Switzerland . Email:
Medchemcomm. 2017 Jun 8;8(8):1604-1613. doi: 10.1039/c7md00213k. eCollection 2017 Aug 1.
A diverse range of selective FGFR4 inhibitor hit series were identified using unbiased screening approaches and by the modification of known kinase inhibitor scaffolds. In each case the origin of the selectivity was consistent with an interaction with a poorly conserved cysteine residue within the middle-hinge region of the kinase domain of FGFR4, at position 552. Targeting this region identified a non-covalent diaminopyrimidine series differentiating by size, an irreversible-covalent inhibitor in which Cys552 undergoes an SNAr reaction with a 2-chloropyridine, and a reversible-covalent inhibitor series in which Cys552 forms a hemithioacetal adduct with a 2-formyl naphthalene. In addition, the introduction of an acrylamide into a known FGFR scaffold identified a pan-FGFR inhibitor which reacted with both Cys552 and a second poorly conserved cysteine on the P-loop of FGFR4 at position 477 which is present in all four FGFR family members.
通过无偏向筛选方法以及对已知激酶抑制剂骨架的修饰,鉴定出了多种选择性FGFR4抑制剂命中系列。在每种情况下,选择性的来源都与FGFR4激酶结构域中间铰链区域内位置552处一个保守性较差的半胱氨酸残基相互作用一致。靶向该区域鉴定出了一个通过大小区分的非共价二氨基嘧啶系列、一种不可逆共价抑制剂(其中Cys552与2-氯吡啶发生亲核芳香取代反应)以及一个可逆共价抑制剂系列(其中Cys552与2-甲酰基萘形成半硫代缩醛加合物)。此外,将丙烯酰胺引入已知的FGFR骨架中鉴定出了一种泛FGFR抑制剂,它与Cys552以及FGFR4 P环上位置477处另一个保守性较差的半胱氨酸发生反应,该半胱氨酸存在于所有四个FGFR家族成员中。